|Bid||40.15 x 800|
|Ask||43.25 x 1300|
|Day's Range||41.40 - 43.10|
|52 Week Range||23.30 - 43.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.40|
Research reports have been issued by WallStEquities.com on BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), Cancer Genetics Inc. (NASDAQ: CGIX), and Check-Cap Ltd (NASDAQ: CHEK). Companies in the Medical Laboratories and Research category is very small from a dividend perspective.
BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market cap had gained 373% between 2013 and 2017.
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
The best performing mutual fund so far this year - beating the S&P 500 by more than 20% - is run by a small-town duo of father and son.
NEW YORK, April 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
On a per-share basis, the Malvern, Pennsylvania-based company said it had net income of 17 cents. Earnings, adjusted for one-time gains and costs, came to 39 cents per share. The results beat Wall Street ...
MALVERN, Pa., April 25, 2018-- BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of ...
MALVERN, Pa., April 19, 2018-- BioTelemetry, Inc. will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held at ...
What: BioTelemetry, Inc. will visit the Nasdaq MarketSite in Times Square in celebration of its 10th listing anniversary. BioTelemetry, Inc. is the leading wireless medical technology company focused on ...
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services, expand in the research market, and leverage its monitoring platform in new markets. In order to increase the demand for its portfolio of outpatient cardiac monitoring solutions, BioTelemetry is focusing on educating cardiologists, electrophysiologists, and neurologists on the benefits of using mobile cardiac telemetry for arrhythmia monitoring while stressing the increased diagnostic yield and ability to deliver more effective treatments.
BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.
BioTelemetry (BEAT) operates in three segments: healthcare, research, and technology. The healthcare segment contributed 81% of BioTelemetry’s total revenues in fiscal 2017. Under this segment, BioTelemetry offers a full spectrum of solutions with a single source of cardiac monitoring services to cardiologists, electrophysiologists, neurologists, and primary care physicians.
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 1, 2018 / Active-Investors.com has just released a free earnings report on Laboratory Corp. of America Holdings (NYSE: ...
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on PerkinElmer, Inc. (NYSE: PKI ). If you ...
BioTelemetry Inc (NASDAQ:BEAT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Malvern, Pennsylvania-based company said it had a loss of 48 cents per share. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results exceeded Wall Street expectations. ...